-
BioArctic Announces New Nomination Committee Ahead of Annual General Meeting
Setting the Stage for Corporate Governance BioArctic AB, the biopharmaceutical company known for its innovative research into neurodegenerative diseases, has officially announced the composition of its Nomination Committee. This process is a key step in preparing for the company’s upcoming Annual General Meeting (AGM). The Role of the Nomination Committee The primary responsibility of the…
-
Kexing Biopharm Makes a Strong Impression at CPhI Milan 2024
Innovation and Global Expansion At the recently concluded CPhI Milan 2024, one of the world’s most prestigious pharmaceutical industry gatherings, Kexing Biopharm showcased its commitment to global innovation and strategic international partnerships. The company’s presence at the event served as a major platform for highlighting its advanced biopharmaceutical capabilities. Strengthening International Ties Kexing Biopharm leveraged…
-
Kexing Biopharm Expands Global Reach at CPHI Milan 2024
A New Milestone in Global Partnerships Kexing Biopharm recently made a significant impact at CPHI Milan 2024, one of the world’s premier pharmaceutical industry events. The company utilized this global stage to showcase its latest advancements in biotechnology and forge new strategic alliances within the international market. Key Highlights from the Event During the exhibition,…
-
New Hope for IBD: Mabwell’s 9MW5211 Receives IND Clearance from NMPA
A Major Milestone in Gastrointestinal Research There is promising news for the inflammatory bowel disease (IBD) community. Mabwell (688062.SH), a leading innovative biopharmaceutical company, has officially announced that its proprietary drug candidate, 9MW5211, has received Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA) of China. Understanding 9MW5211 The clinical advancement of…